EUVIMEDEUVIMED entdecken
Open Access

Variation in Opioid Agonist Dosing in Clinical Trials by Race and Ethnicity

Rachael K Ross, Shodai Inose, Matisyahu Shulman, Edward V Nunes, Lauren C Zalla, A Kathleen Burlew, Kara E Rudolph

JAMA Network Open · 2024

DOI: 10.1001/jamanetworkopen.2024.36612 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, 2024. Verfasst von Rachael K Ross und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York. Hauptthemen laut MEDLINE: Analgesics, Opioid, Buprenorphine, Methadone, Opiate Substitution Treatment. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIDA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Racial and ethnic disparities in access to treatment and quality of treatment for opioid use disorder (OUD) have been identified in usual care settings. In contrast, disparities in treatment quality within clinical trials are relatively unexamined.

Objective

To estimate racial and ethnic differences in the dose of opioid agonist treatment for OUD in the first 4 weeks of treatment in clinical trials. Design, Setting, and Participants This cohort study performed analysis of the methadone and buprenorphine treatment arms of 3 trials conducted by the National Institute on Drug Abuse Clinical Trials Network between May 2006, and January 31, 2017, at multiple Clinical Trials Network sites across the US. Trial participants who were randomized to and initiated buprenorphine or methadone treatment and who identified as Hispanic, non-Hispanic Black, or non-Hispanic White were included in the present study. Data were analyzed from November 1, 2023, to August 5, 2024. Exposure Combined race and ethnicity as self-classified by the patient at trial enrollment. Main Outcomes and Measures The maximum daily dose of buprenorphine or methadone received in each week for the first 4 weeks of treatment. The mean dose and the percentage of patients receiving a higher dose (buprenorphine ≥ 16 mg and methadone ≥ 60 mg) were compared across race and ethnicity groups.

Results

A total of 1748 patients (1263 who initiated buprenorphine and 485 who initiated methadone treatment) were included in the analysis (1168 [66.8%] male; median age, 33 [IQR, 26-45] years). Of these, 138 patients (7.9%) identified as Black, 273 (15.6%) as Hispanic, and 1337 (76.5%) as White. In week 4, Black patients received buprenorphine doses 2.5 (95% CI −4.6 to −0.5) mg lower and methadone doses 16.7 (95% CI, −30.7 to −2.7) mg lower compared with White patients, after standardizing by age and sex. In week 4, the percentage of patients receiving a higher dose of medication (buprenorphine ≥ 16 mg; methadone ≥ 60 mg) was 16.9 (95% CI, −31.9 to −1.9) points lower for Black patients compared with White patients. Hispanic and White patients received similar buprenorphine doses; Hispanic patients received lower methadone doses than White patients. Conclusions and Relevance In this cohort study of data from 3 clinical trials, White patients generally received higher doses of medication than Black patients. Future research is needed to understand the mechanisms of and interventions to reduce disparities in OUD treatment quality and how such disparities impact generalizability of trial results.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Analgesics, OpioidBuprenorphineMethadoneOpiate Substitution TreatmentOpioid-Related DisordersAdultFemaleHumansMaleMiddle AgedBlack or African AmericanCohort StudiesDose-Response Relationship, DrugEthnicityHispanic or LatinoUnited StatesWhite

Substanzen

Analgesics, OpioidBuprenorphineMethadone

Autor:innen und Institutionen

  • Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York.
  • Department of Psychiatry, Columbia University Irving Medical Center, Columbia University, New York, New York.
  • New York State Psychiatric Institute, New York, New York.
  • Department of Epidemiology, Bloomberg School of Public Health, The Johns Hopkins University, Baltimore, Maryland.
  • Department of Psychology, University of Cincinnati, Cincinnati, Ohio.

Förderung

  • NIAID NIH HHS
  • NIDA NIH HHS

Zitieren

APA

Ross, R. K., Inose, S., Shulman, M., Nunes, E. V., Zalla, L. C., Burlew, A. K., & Rudolph, K. E. (2024). Variation in Opioid Agonist Dosing in Clinical Trials by Race and Ethnicity. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2024.36612

Vancouver

Ross RK, Inose S, Shulman M, Nunes EV, Zalla LC, Burlew AK, et al. Variation in Opioid Agonist Dosing in Clinical Trials by Race and Ethnicity. JAMA Network Open. 2024. doi:10.1001/jamanetworkopen.2024.36612

BibTeX
@article{Ross2024,
  author = {Ross, Rachael K and Inose, Shodai and Shulman, Matisyahu and Nunes, Edward V and Zalla, Lauren C and Burlew, A Kathleen and Rudolph, Kara E},
  title = {Variation in Opioid Agonist Dosing in Clinical Trials by Race and Ethnicity},
  journal = {JAMA Network Open},
  year = {2024},
  doi = {10.1001/jamanetworkopen.2024.36612}
}
Kostenlos starten →